Common drug may shield kidneys from chemo harm

NCT ID NCT05640817

Completed Symptom relief Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether pentoxifylline, a drug used for blood flow problems, can protect the kidneys from damage caused by cisplatin chemotherapy in head and neck cancer patients. 90 adults receiving cisplatin for the first time took part. Researchers measured kidney injury using standard tests and a specific marker called KIM-1.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pentoxifylline
What this could lead to: If it works, this could offer a simple way to reduce kidney damage from cisplatin chemotherapy, helping patients complete their cancer treatment with fewer side effects.
What could go wrong: This is a small, completed study without a phase designation, so results may not be definitive. Pentoxifylline may not provide meaningful protection for all patients, and its benefits need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cisplatin toxicity head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PENTOXIFYLLINE, CISPLATIN, NEPHROTOXIXCITY

Contacts and locations

Locations

Tanta Unuversity

Tanta, 34518, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.